RBFC
NVO

Roman Butler Fullerton & Co’s Novo Nordisk NVO Stock Holding History

Roman Butler Fullerton & Co’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-3,869
Closed -$277K – 269
2025
Q2 		$277K Buy
+3,869
New +$263K 0.08% 198
2024
Q3 		– Sell
-3,294
Closed -$470K – 257
2024
Q2 		$470K Buy
+3,294
New +$436K 0.15% 140

Other funds holding NVO

Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return
Fayez Sarofim & Co
Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Roman Butler Fullerton & Co's NVO Position: Q3 2025 in Review

Roman Butler Fullerton & Co sold out of Novo Nordisk (NVO) in Q3 2025, closing a stake of 3,869 shares — an estimated $277K sold.

Roman Butler Fullerton & Co first reported a position in NVO in Q2 2024 and held it in 2 quarters. The position peaked at $470K in Q2 2024. 1,395 funds tracked by Wall St. Rank hold NVO as of Q3 2025.

  • Roman Butler Fullerton & Co reported no remaining Novo Nordisk position as of Q3 2025 after selling out during the quarter.
  • Roman Butler Fullerton & Co sold 3,869 Novo Nordisk shares in Q3 2025, an estimated $277K.
  • Roman Butler Fullerton & Co first reported a position in Novo Nordisk in Q2 2024 and held it in 2 quarters.
  • Roman Butler Fullerton & Co's Novo Nordisk position peaked at $470K in Q2 2024.
  • 1,395 funds tracked by Wall St. Rank held Novo Nordisk as of Q3 2025.

Based on Roman Butler Fullerton & Co's 13F filing for Q3 2025, filed 6 Nov 2025.